Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study

<u><i></i></u> <u><i>Background:</i></u> Atopic dermatitis (AD) is linked to increased cardiovascular risk. While GLP-1 receptor agonists (GLP-1RAs) show cardiometabolic benefits in the general population, their impact in patients with AD remains unclear.<u><i>Objective:</i></u> To evaluate whether GLP-1RA use is associated with a reduced risk of major adverse cardiovascular events (MACE) in patients with AD.<u><i>Methods:</i></u> This retrospective cohort study used TriNetX Research Network. Patients with AD ≥12 years old who used GLP-1RAs between April 2005 and December 2020 were 1:1 propensity-score matched to patients with AD not on GLP-1RA by demographic and cardiovascular risk factors. The primary outcome was incidence of MACE (cerebrovascular disease [CVD], heart failure [HF], atherosclerosis, ischemic heart disease [IHD], and percutaneous coronary intervention [PCI]) at 5, 10, and 20 years post-index date.<u><i>Results:</i></u> Of the 547,246 patients with AD, 24,936 (4.6%) used GLP-1RAs. After propensity-matching, at 20 years, patients with AD on GLP-1RA had lower odds of CVD (adjusted odds ratio [aOR] 0.718 [0.643-0.800]), HF (aOR 0.791 [0.732-0.854]), atherosclerosis (aOR 0.768 [0.715-0.826]), and IHD (aOR 0.900 [0.841, 0.963]), compared with patients with AD not using GLP-1RAs.<u><i>Conclusions:</i></u> In patients with AD, GLP-1RA use was associated with a reduced long-term risk of CVD, HF, IHD, and atherosclerosis, highlighting their potential cardiometabolic benefit in this population.